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Abstract
Background: Signaling pathways that converge on two different transcription factor complexes, NFκB and AP-1, have been
identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen.
Methods: Two cell line models of tamoxifen-resistant ER-positive breast cancer, MCF7/HER2 and BT474, showing increased
AP-1 and NFκB DNA-binding and transcriptional activities, were studied to compare tamoxifen effects on NFκB and AP-1
regulated reporter genes relative to tamoxifen-sensitive MCF7 cells. The model cell lines were treated with the IKK inhibitor
parthenolide (PA) or the proteasome inhibitor bortezomib (PS341), alone and in combination with tamoxifen. Expression
microarray data available from 54 UCSF node-negative ER-positive breast cancer cases with known clinical outcome were used
to search for potential genes signifying upregulated NFκB and AP-1 transcriptional activity in association with tamoxifen
resistance. The association of these genes with patient outcome was further evaluated using node-negative ER-positive breast
cancer cases identified from three other published data sets (Rotterdam, n = 209; Amsterdam, n = 68; Basel, n = 108), each
having different patient age and adjuvant tamoxifen treatment characteristics.
Results: Doses of parthenolide and bortezomib capable of sensitizing the two endocrine resistant breast cancer models to
tamoxifen were capable of suppressing NFκB and AP-1 regulated gene expression in combination with tamoxifen and also
increased ER recruitment of the transcriptional co-repressor, NCoR. Transcript profiles from the UCSF breast cancer cases
revealed three NFκB and AP-1 upregulated genes – cyclin D1, uPA and VEGF – capable of dichotomizing node-negative ER-positive
cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases. Across
the four independent sets of node-negative ER-positive breast cancer cases (UCSF, Rotterdam, Amsterdam, Basel), high
expression of all three NFκB and AP-1 upregulated genes was associated with earliest metastatic relapse.
Conclusion: Altogether, these findings implicate increased NFκB and AP-1 transcriptional responses with tamoxifen resistant
breast cancer and early metastatic relapse, especially in younger patients. These findings also suggest that agents capable of
preventing NFκB and AP-1 gene activation may prove useful in restoring the endocrine responsiveness of such high-risk ER-
positive breast cancers.
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Background
Intracellular responses of ER-positive breast cancers to
selective estrogen receptor modulators (SERMs) like
tamoxifen are dependent on two different ER-regulated
gene mechanisms: one in which liganded ER binds pro-
moter DNA at an estrogen responsive element (ERE), and
another in which ER becomes tethered to other promoter-
bound transcription factors [1,2]. Nuclear receptors like
ER also produce their promoter-regulating effects via lig-
and-dependent recruitment of co-regulatory factors
known as coactivators or corepressors [3-5].
Exhibiting a diverse array of chromatin-modifying activi-
ties, coactivators (e.g. SRC1, AIB1/SRC-3, TIF2, CBP/
p300, PCAF) mediate the transcription promoting activity
of liganded ER whether it is ERE bound or tethered to
another promoter-bound complex like AP-1, NFκB, Sp1
or C/EBPβ. Alternatively, the transactivating potential of
ER may be repressed by recruitment of a transcriptional
corepressor (e.g. NCoR1, SMRT, REA, RIP140) with its
associated histone deacetylase activity. The intracellular
balance of coactivator-corepressor activity appears to
determine, at least in part, whether the net cellular
response to tamoxifen-bound ER is agonistic or antago-
nistic. Much of the antagonistic ER response to tamoxifen
is mediated by NCoR1 [6]; and reduced NCoR1 expres-
sion in ER-positive primary breast cancers predicts for
tamoxifen resistance and early metastatic relapse [7].
However, in several tamoxifen-resistant ER-positive breast
cancer models, including those induced by activated
ERBB2, a chemical perturbation in the ER DNA-binding
domain can reverse tamoxifen resistance by decreasing ER
association with AIB1 and increasing its association with
NCoR1, without altering cellular expression levels of these
two ER co-regulators [8].
Less well appreciated are the intracellular consequences of
tamoxifen-liganded ER in association with elevated AP-1
and NFκB transcriptional activities. ER and NFκB are
known to be mutually inhibitory at several levels [9]; and
it has been suggested that in some ER-positive breast can-
cers SERMS like tamoxifen can activate NFκB, stimulate
cell growth and survival, and thereby contribute to endo-
crine resistance [10]. Recent clinical evidence suggests that
increased NFκB activation, in concert with activated AP-1,
identifies a high-risk subset of hormone-dependent breast
cancers destined for early relapse on adjuvant tamoxifen
therapy [11]. Unlike its interference with NFκB, ER can be
recruited by DNA-bound heterodimers from the AP-1
family of b-zip transcription factors; and, dependent on
tissue type and balance of nuclear co-regulators,
tamoxifen-bound ER that is antagonistic on an ERE-
driven gene promoter may be agonistic on an AP-1 driven
gene promoter [12-15]. In ER-positive MCF7 cells, upreg-
ulated AP-1 activity has been associated with antiestrogen
resistance [16]; and in clinical samples of ER-positive
breast cancers, tamoxifen resistance has been associated
with upregulated AP-1 activity [17].
To model the impact of tamoxifen-liganded ER on NFκB
and AP-1 regulated genes, luciferase reporter genes driven
by ERE, NFκB or AP-1 were transfected into ER-positive
human breast cancer cells shown to possess basal (MCF7)
or activated (MCF7/HER2, BT474) NFκB and AP-1 tran-
scriptional activities. NFκB and AP-1 inhibiting doses of
parthenolide or bortezomib/PS341, capable of enhancing
tamoxifen inhibition of MCF7/HER2 and BT474 growth,
were shown to increase recruitment of NCoR1 by endog-
enous ER in these cells and, relative to MCF7 cells,
enhance the antagonistic and inhibitory effects of
tamoxifen on both NFκB and AP-1 reporter genes. Finally,
to explore the potential of linking genes upregulated by
both NFκB and AP-1 with tamoxifen resistance, expres-
sion microarray data available from 54 node-negative ER-
positive breast cancers revealed three such genes capable
of dichotomizing these cases into early and late relapsing
subsets despite adjuvant tamoxifen therapy: cyclin D1, uPA
and VEGF. The prognostic association of these genes with
patient outcome was further evaluated using node-nega-
tive ER-positive breast cancer cases identified from three
other published data sets (Rotterdam, n = 209; Amster-
dam, n = 68; Basel, n = 108), each having different patient
age and adjuvant tamoxifen treatment characteristics.
Methods
Reagents, breast cancer cell lines, and drug response 
interactions
Unless otherwise specified, all reagents were purchased
from Sigma Chemical Co. (St. Louis, MO), including
tamoxifen (TAM; [Z]-1- [p-dimethylaminoethoxyphenyl]-
1,2-diphenyl -1 butene). Parthenolide (PA) was pur-
chased from Alexis Biochemicals (San Diego, CA); and
bortezomib (PS341) was kindly provided by Millennium
Pharmaceuticals Inc. (Cambridge, MA). The ER-positive/
ERBB2-negative MCF7 and ER-positive/ERBB2-positive
BT474 human breast cancer cell lines were obtained from
the American Type Culture Collection (Rockville, MD)
and were maintained at 37°C and 5% CO2 in Dulbecco's
modified Eagle's medium (DMEM) for MCF7 or RPMI-
1640 medium for BT474, supplemented with 10% fetal
bovine serum (FBS), 1% penicillin-streptomycin, and 10
ng/ml insulin. Media and supplements were purchased
from Mediatech, Inc. (Herndon, VA). The ER-positive/
ERBB2-positive subline, MCF7/HER2 (clone-18), was
maintained like parental MCF7 cells except for selection
under G418 as originally reported [18]. Data from previ-
ously reported experiments were re-analyzed to determine
TAM-PA and TAM-PS341 treatment interactions [11,19].
Relative to vehicle (DMSO or ethanol) treated controls,
single agent and combined treatments (at indicated doseBMC Cancer 2007, 7:59 http://www.biomedcentral.com/1471-2407/7/59
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and duration) were assessed after plating 104 cells (MCF7,
MCF7/HER2, BT474) in 24-well microtiter dishes by sul-
forhodamine B (SRB) viability assay. Expected (E) degrees
of growth inhibition following TAM-PA or TAM-PS341
treatment combinations were determined based on inde-
pendent probabilities of proportional growth reduction,
and these were compared with observed (O) degrees of
growth reduction (control = 1.0 or 100%). Following rep-
licate testing (three independent experiments in quadru-
plicate), mean ± SEM O/E values were calculated and the
significance (p-values) for O/E reductions in MCF7/HER2
or BT474 relative to MCF7 cells were determined by
ANOVA and t testing.
Immunoprecipitation, immunoblotting and DNA-binding 
assays
Whole cell lysates were used for immunoprecipitation
and immunoblotting. Cells were extracted in NP-40
buffer containing 50 mM Hepes (pH 7.4), 150 mM NaCl,
1% Nonidet P-40, 25 μM β-glycerol phosphate, 25 mM
sodium fluoride, 5 mM EGTA, 1 mM EDTA, 1 mM sodium
vanadate, and a cocktail of mini-complete protease inhib-
itors (Roche Diagnostics, Mannheim, Germany). Protein
aliquots of 15–30 μg were separated by gel electrophoresis
in 4–12 % Bis-Tris SDS gradient gels in morpholinepro-
pane sulfonic acid (MOPS) running buffer. Proteins trans-
ferred onto polyvinylidene difluoride (PVDF) membranes
were first blocked (5% non-fat milk in PBS containing
0.1% Tween-20) and then incubated overnight with anti-
bodies specific to ERα, p50, p65, or bcl-3 (Santa Cruz Bio-
technology Inc., Santa Cruz, CA). Immunoreactive bands
were visualized with horseradish peroxidase-conjugated
goat-anti-mouse IgG (BioRad, Hercules, CA) and chemi-
luminescence enhancement reagents (Pierce, Rockford,
IL). Membranes were then stripped and reblotted with β-
actin antibody (Abcam Inc., Cambridge, MA) to normal-
ize for protein loading. For immunoprecipitation (IP) fol-
lowed by Western blotting (WB), 300 μg protein aliquots
were first incubated with 10 μl of p50 or NCoR antibody
solution (Santa Cruz Biotechnology Inc., Santa Cruz, CA)
for 2 hours (4°C) under continuous agitation. Immune
complexes were recovered by adding 25 μl of Protein A-
Sepharose beads (Amersham Biosciences, Uppsala, Swe-
den), washing × 5 in lysis buffer, and resuspending in 3 ×
Laemmli sample buffer prior to gel electrophoresis and
immunoblotting, as described above.
Transient transfection and luciferase reporter assays
Cultures were seeded one day before transfection with
luciferase (luc) reporters to a density of 1–2 × 103 cells per
well in 96-well microtiter plates and using appropriate
growth media. Cells were transiently transfected with
either 0.5 μg of (ERE)3-tk-luc reporter plasmid (Promega,
Madison, MI) or 0.5 μg of (NFκB)-luc or (AP-1)-luc
reporter plasmid (Stratagene, La Jolla, CA), along with
FuGene 6 transfection reagent (Roche, Indianapolis, IN).
The Renilla luciferase vector pRL-tk-luc (Promega, Madi-
son, MI) was co-transfected to normalize for transfection
efficiency. Culture media was changed 20 h following
transfection and cells were then treated with PS341 (10
nM, 25 nM) or PA (1 μM, 5 μM), alone or in combination
with 500 nM TAM for 24 h. Cells were subsequently
washed with PBS, lysed for Dual-Glo™ luciferase assay
(Promega), and reporter activity measured by luminome-
ter. The ratio of firefly luminescence/Renilla luminescence
was used for comparison of AP-1 and NFκB driven gene
activities in the untreated cell lines. All other transfections
were reported as fold-changes in luciferase activity over
vehicle treated controls. All transient transfection and
reporter gene results are presented as mean values (± SEM)
from at least three independent experiments using quad-
ruplicate conditions. MCF7/HER2 and BT474 results
showing significant differences (p < 0.05) from compara-
bly treated MCF7 controls were determined by one-way
ANOVA and t testing.
Breast cancer datasets and genes upregulated by NFκB 
and AP-1
Cryobanked breast cancer specimens were obtained from
the University of California San Francisco (UCSF) Com-
prehensive Cancer Center Breast Oncology Program Tis-
sue Core, and collected under UCSF approved protocols
following patient consent. From an archive of over 1,000
liquid nitrogen frozen breast cancer specimens, 54 pri-
mary breast cancer samples (UCSF cases) had been iden-
tified for other study purposes [20], using the following
criteria: early clinical stage (T1/2, N0, M0) invasive breast
cancer, ER-positive status (>10% nuclear immunohisto-
chemical staining), known primary systemic therapy
(treatment era: 1989–2004, with 33/54 receiving adjuvant
tamoxifen and 18/54 receiving adjuvant chemotherapy),
known clinical outcome (relapse-free survival, RFS), and
stratification into young (≤ 45 years, n = 29) or old (≥ 70
years, n = 25) age-at-diagnosis. The age stratification
groups were balanced for standard prognostic markers
(tumor size, grade, proliferation index, ERBB2 status) and
adjuvant therapy, but showed differences in clinical out-
come with the younger cases experiencing more frequent
(7/29) and earlier metastatic relapses (median RFS = 4.84
years, range 0.13–14.14 years) than the older age-at-diag-
nosis cases (2/25; median RFS = 5.52 years, range 0.74–
12.72 years). Sample requirements also included a mini-
mum frozen-wet weight of 100 mg and histologic confir-
mation of >50% cancer cells per sample section. Total
RNA from each tissue sample was formamide extracted,
purified and reconstituted in aqueous solution using RNe-
asy (Qiagen, CA) according to manufacturer's instruc-
tions; and the resulting RNA samples were quality verified
by micro-analysis (Agilent Bioanalyzer, CA). Total RNA
(3–5  μg per sample) was labeled and analyzed usingBMC Cancer 2007, 7:59 http://www.biomedcentral.com/1471-2407/7/59
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Affymetrix (Santa Clara, CA) high-density oligonucleotide
microarrays, HG-U133A (v2), in 96-well chips each with
22.2 K annotated probes representing ~13 K unique Uni-
genes. Gene expression analysis was performed using
standard Affymetrix procedures within the Lawrence Ber-
keley National Lab and Life Science Division's Molecular
Profiling Laboratory (MPL). Probe set measurements were
generated from quantified Affymetrix image files (.CEL
files) using the RMA algorithm from BioConductor R. The
resulting data matrix consisted of normalized log abun-
dance values for each probe set and sample; these data
files and associated clinical parameters for each sample
have been entered into the NCBI Gene Expression Omni-
bus (GEO) repository (GSE7378). Gene expression values
were mean centered, and a low variation filter was applied
to exclude probe sets that did not have at least 5 observa-
tions exhibiting a two-fold change from the mean. While
arbitrary, this filter restriction was based on accepted cri-
teria [21]. Filtered probes were annotated by GeneTraffic
software (MPL) and those with unknown Unigene iden-
tity were omitted, yielding a final significant set of 5,523
probes representing 4,332 unique genes. This significant
probe set was searched for genes reported to be coordi-
nately upregulated by both NFκB and AP-1 [22-26]. To
dichotomize the 54 tumor samples according to levels of
expression for each of the NFκB and AP-1 upregulated
genes identified in the significant probe set, samples with
positive mean-centered transcript values were designated
as "high" expressors while those with negative mean-cen-
tered values were classified as "low" expressors. Kaplan-
Meier RFS curves were produced for each of the high/low
dichotomizations, and Log Rank analysis was used to
determine statistical significance between survival curves
(StatView, SAS Institute Inc).
Three other independent data sets were used to evaluate
the prognostic value of the NFκB and AP-1 upregulated
genes identified from the UCSF dataset. Node-negative
ER-positive breast cancer cases were identified from pub-
lished Amsterdam (n = 68), Rotterdam (n = 209) and
Basel (n = 108) gene expression studies, each consisting of
cases with different age and adjuvant tamoxifen treatment
characteristics (21, 27, 28). The Amsterdam dataset was
obtained through the Rosetta Inpharmatics publications
archive and consisted of breast cancers diagnosed in
younger age (< 55 years) patients, of which 95% received
no adjuvant therapy [21]; corresponding gene probes
were identified by UniGene symbols. The Rotterdam data-
set was obtained through the NCBI/Genbank GEO data-
base (GSE2034) and consisted of breast cancers
diagnosed in patients with ages ranging from 26–83 years,
none of whom received any adjuvant therapy [27]; corre-
sponding gene probes were identified by Affymetrix iden-
tification numbers, and when a gene was represented by
multiple probes, the average expression value was calcu-
lated. The node-negative ER-positive Basel dataset was
extracted from a previously reported study population,
and consisted of breast cancers diagnosed in patients with
ages ranging from 37–84 years, the majority of whom
(70%) received adjuvant tamoxifen therapy [28]. For the
Amsterdam dataset, gene expression levels were deter-
mined using an Agilent microarray platform; positive
log10(ratio) values were designated as "high" expressors,
while those with negative log10(ratio) values were desig-
nated as "low" expressors. For the Rotterdam dataset, gene
expression levels were determined using an Affymetrix
microarray platform; positive mean centered values were
designated as "high" expressors and negative mean cen-
tered values were designated as "low" expressors. For the
Basel dataset, a median cut-point was applied to the quan-
titative real-time PCR data to dichotomize the samples
into "high" vs. "low" expressors. Kaplan-Meier metastasis
free survival curves were produced for each of the high/
low dichotomizations, and Log Rank analysis was used to
determine statistical significance between survival curves.
Results
Tamoxifen resistant breast cancer models show enhanced 
NFκB and AP-1 transcriptional activity
To study the effects of NFκB and AP-1 upregulated gene
expression in ER-positive breast cancer cells, two TAM-
resistant ER-positive/ERBB2-positive breast cancer cell
lines, MCF7/HER2 and BT474, were evaluated in relation
to TAM-sensitive ER-positive/ERBB2-negative MCF7 cells.
Figure 1 demonstrates the 2-to-3 fold increased levels of
NFκB DNA-binding and NFκB driven reporter gene (luci-
ferase) expression in both MCF7/HER2 and BT474 com-
pared to MCF7 (panels B and C, respectively), despite
comparable levels of NFκB p65 and p50 component pro-
teins in all three cell lines (panel A). Since the increased
NFκB activation in both MCF7/HER2 and BT474
appeared largely due to increased p50 DNA-binding
(panel B), and NFκB p50 is known to lack a transactiva-
tion domain and require Bcl-3 binding to become tran-
scriptionally competent [29-31], IP-immunoblotting was
used to demonstrate that the p50 extracted from BT474
and MCF7/HER2 were associated with 3-to-4 fold more
Bcl-3 than the p50 extracted from MCF7 cells (panel A).
Similarly, Figure 2 demonstrates that while MCF7/HER2
and BT474 exhibited only about 2-fold greater AP-1 DNA-
binding over MCF7, largely composed of phospho-c-Jun
(panel A), these cell lines showed at least 10-to-30 fold
greater levels of AP-1 driven reporter gene activity (panel
B). Altogether, Figure 1 and 2 findings confirm that the
ER-positive/ERBB2-positive MCF7/HER2 and BT474 cell
lines contain significantly greater levels of NFκB and AP-1
activity relative to the ER-positive/ERBB2-negative MCF7
cells.BMC Cancer 2007, 7:59 http://www.biomedcentral.com/1471-2407/7/59
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Enhanced tamoxifen responsiveness associated with 
suppression of NFκB and AP-1 regulated gene expression
Previous studies have adequately demonstrated that ER-
positive/ERBB2-positive breast cancer models simulate
clinical cases by exhibiting TAM-resistance relative to
TAM-sensitive ER-positive/ERBB2-negative models and
cases [18,32,33]. These same TAM-resistant ER-positive/
ERBB2-positive models have been used to demonstrate
that NFκB inhibiting doses of the IKK inhibitor, partheno-
lide (PA), or the proteasome inhibitor, bortezomib
(PS341), can be used to significantly improve sensitivity
to TAM [11]. Data from these previous experiments [11]
were re-analyzed to quantitate TAM-PA and TAM-PS341
treatment interactions in MCF7/HER2 and BT474 cells
relative to MCF7, as shown in the O/E values presented in
Table 1. BT474 cells showed somewhat greater synergistic
TAM-PA and TAM-PS341 interactions relative to
MCF7HER2 cells for the two PA (1, 5 μM) and PS341 (10,
25 nM) doses; still, the greater than additive interactions
observed in TAM-resistant MCF7/HER2 relative to the
TAM-sensitive MCF7 resulted in comparable final growth
inhibitory effects in both cell lines treated with these TAM
combinations. To understand the basis for these synergis-
tic TAM-PA and TAM-PS341 growth inhibitory responses,
gene reporter studies were performed in cell cultures
treated for 24 h with the same drug doses and combina-
tions shown in Table 1.
Treatment for 24 h with either PA (1, 5 μM) or PS341 (10,
25 nM), alone or in combination with TAM (500 nM), did
not affect protein expression of ERα, PRA or PRB (data not
shown) in any of the cell lines. The gene-regulating effects
of PA and PS341, alone and in combination with TAM,
were evaluated in MCF7, MCF7/HER2 and BT474 cells
transiently transfected with luciferase (luc) reporter con-
structs driven by either ERE, NFκB or AP-1 regulated pro-
moters. Figure 3A shows that TAM alone significantly
inhibited (ERE)-luc activity in TAM-sensitive MCF-7 cells
Increased DNA-binding and transcriptional activity of NFκB complexes expressed in TAM-resistant (MCF7/HER2, BT474) rel- ative to TAM-sensitive (MCF7) breast cancer cells Figure 1
Increased DNA-binding and transcriptional activity of NFκB complexes expressed in TAM-resistant (MCF7/HER2, BT474) rel-
ative to TAM-sensitive (MCF7) breast cancer cells. A. Whole cell lysates were immunoblotted to compare endogenous pro-
tein expression of p50, p65, and bcl-3 components relative to β-actin. Aliquots were also immunoprecipitated (IP) with 
antibody to p50, and subsequently Western blotted (WB) to detect bcl-3 complexed to p50 relative to total immunoprecipi-
tated p50. B. DNA-binding by individual NFκB p50 and p65 subunits from nuclear extracts, quantitated by ELISA-based Trans-
AM™ assays (mean ± SE OD450nm values from triplicate samples). C. (NFκB)-luciferase reporter gene expression (mean ± SE 
values from triplicate samples) measured after transient co-transfection of cells with the firefly reporter plasmid and a Renilla 
luciferase vector for normalization, as described in Methods. Asterisks (*) indicate significant difference (p < 0.05) from control 
MCF7 values.
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but not in TAM-resistant MCF7/HER2 or BT474 cells. In
contrast, as single agents PA and PS341 inhibited (ERE)-
luc activity in MCF7/HER2 and BT474 cells but not in
MCF7 cells; and TAM combinations with either PA or
PS341 produced no significant further reductions in
(ERE)-luc activity over that produced by PA or PS341
alone. Unlike the treatment effects on (ERE)-luc expres-
sion in all three cell lines, NFκB and AP-1 driven reporters
showed no treatment responses in TAM-sensitive MCF7
cells. Following the same drug dosing associated with syn-
ergistic TAM-PA and TAM-PS341 growth inhibitory
responses in MCF7/HER2 and BT474 cells (Table 1), Fig-
ure 3B shows synergistic suppression of (NFκB)-luc
expression only in the NFκB overexpressing TAM-resistant
models. Likewise, and with the single exception of TAM-
PA treatment in BT474 cells, Figure 3C shows significant
synergistic suppression of (AP-1)-luc expression only in
AP-1 overexpressing TAM-resistant models.
Enhanced tamoxifen responsiveness associated with ER 
recruitment of the co-repressor, NCoR
TAM-PA and TAM-PS341 drug combinations associated
with synergistic growth inhibition and reductions in
NFκB and AP-1 driven reporter gene expression were also
evaluated with regard to ER recruitment of the transcrip-
tional co-repressor, NCoR. As shown in the IP-immunob-
lots of Figure 4, neither PA nor PA341, administered as
single agents, produced any significant change in MCF7,
MCF7/HER2 or BT474 levels of co-repressor bound to ER.
As would be expected in TAM-sensitive cells, within 24 h
of TAM treatment MCF7 showed a >3 fold increase in the
amount of NCoR-bound ER. In contrast, TAM-resistant
MCF7/HER2 and BT474 showed little if any TAM induced
change in NCoR-bound ER. After combination treatment
with either TAM-PA or TAM-PS341, MCF7/HER2 and
BT474 showed levels of NCoR-bound ER approaching
that seen in treated MCF7 cells.
Analysis of ER-positive primary breast cancers for NFκB 
and AP-1 upregulated genes
Given the fact that our TAM-resistant breast cancer mod-
els, MCF7/HER2 and BT474, showed activation of both
NFκB and AP-1 transcription factor complexes by both
DNA-binding and reporter gene assays, we performed an
exploratory analysis in a UCSF dataset of 54 ER-positive,
node-negative primary human breast cancers looking for
Increased DNA-binding and transcriptional activity of AP-1 complexes expressed in TAM-resistant (MCF7/HER2, BT474) rela- tive to TAM-sensitive (MCF7) breast cancer cells Figure 2
Increased DNA-binding and transcriptional activity of AP-1 complexes expressed in TAM-resistant (MCF7/HER2, BT474) rela-
tive to TAM-sensitive (MCF7) breast cancer cells. A. DNA-binding by individual phospho-c-Jun and c-Fos subunits from 
nuclear extracts, quantitated by ELISA-based Trans-AM™ assays (mean ± SE OD450 nm values from replicate samples). B. (AP-
1)-luciferase reporter gene expression (mean ± SE values from triplicate samples) measured after transient co-transfection of 
cells with the firefly reporter plasmid and a Renilla luciferase vector for normalization, as described in Methods. Asterisks (*) 
indicate significant difference (p < 0.05) from control MCF7 values.
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prognostic genes known to be upregulated by activated
NFκB and AP-1. Using a commercial expression micro-
array platform and standard filtering criteria, 4,332
unique genes were found to be variably expressed within
this set of histologically similar, early-stage ER-positive
breast cancers. Interestingly, the transcript levels for many
NFκB constituents, including p50/NFKB1, p60, p65/RelA,
RelB, and NFKB1A/IKBα did not pass a commonly used
low variation expression threshold. Only one NFκB
related probe (c-Rel) showed sufficient expression varia-
tion to be included in the significant probe set. In con-
trast, six AP-1 components passed the low variation
expression filter, including c-Jun, JunB, JunD, c-Fos, FosB,
and  Fra2. Except for JunD, none of these variably
expressed NFκB or AP-1 components showed any signifi-
cant association with patient outcome. Among NFκB and
AP-1 regulated genes showing sufficient expression varia-
tion were three probes for VEGF, two probes each for uPA
and  cyclin D1, and one probe each for MMP9,  CCL2,
ICAM1, AGT and BF. Several other well known NFκB reg-
ulated genes (e.g. COX2, TNF, LTA, CSF2, CSF3, IFNB1,
IFNG, IL-6, IL-8) failed to pass the low variation filtering
criteria for admission into the significant probe set
expressed by these early-stage ER-positive breast cancers.
Microarray determined "high" vs. "low" transcript levels
for the eight NFκB and AP-1 regulated genes variably
expressed in the 54 UCSF breast cancer cases were evalu-
ated in relation to patient relapse-free survival (RFS),
adjusted for prior adjuvant tamoxifen use and patient age-
at-diagnosis. Of these, only VEGF,  uPA  and  cyclin D1
showed significant outcome associations with RFS as
shown in the Kaplan-Meier plots of Figure 5, indicating
that high expressors for each of the three genes repre-
sented cases most likely to relapse. Of interest, the prog-
nostic value of these three NFκB and AP-1 regulated genes
measured by separation between RFS curves, appeared
greater for the younger age cases (≤ age 45 years) in which
metastatic relapses occurred earlier and more frequently
relative to the older age cases (≥ 70 years), despite the fact
that tumors from both age cohorts were indistinguishable
with regard to standard prognostic tumor markers, use of
systemic adjuvant therapy, and level of expression for
each of these genes. Over 60% of these cases were treated
with adjuvant tamoxifen, and since recurrences among
both older and younger cases occurred independent of
adjuvant tamoxifen and usually within 5 years of diagno-
sis, relapsing breast cancers were considered tamoxifen
resistant. All 54 cases could be designated as either high
(H) or low (L) expressors for each of the three NFκB and
AP-1 regulated genes and, thus, combinatorially subdi-
vided into four categories (HHH, n = 10; HHL, n = 16;
HLL, n = 14; LLL, n = 14). Kaplan-Meier analyses demon-
strated significantly worse RFS according to the number of
Table 1: Treatment interactions between TAM-PS341 and TAM-PA in ER-positive breast cancer models.
A.
MCF7 MCF7/HER2 BT474
T A M  ( 5 0 0  n M ) ++++++
PS341 (nM) 10 25 10 25 10 25
% of control:
O b s e r v e d  ( O ) 7 16 07 76 14 83 5
E x p e c t e d  ( E ) 6 25 38 37 28 05 9
Ratio: O/E 1.2 1.1 0.93* 0.84* 0.59* 0.59*
B.
MCF7 MCF7/HER2 BT474
T A M  ( 5 0 0  n M ) ++++++
Parthenolide 
(μM)
151515
% of control:
O b s e r v e d  ( O ) 9 14 48 54 47 2 8
E x p e c t e d  ( E ) 8 84 28 45 28 11 3
Ratio: O/E 1.03 1.05 1.01 0.85* 0.89* 0.62*
*p < 0.01 for comparison with MCF7; primary data as originally reported (11).BMC Cancer 2007, 7:59 http://www.biomedcentral.com/1471-2407/7/59
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high expressing NFκB and AP-1 regulated genes (Log Rank
p = 0.03), with those cases showing high expression of all
three genes (HHH) exhibiting a median RFS of < 5 years
(data not shown).
As shown in the Kaplan-Meier plots of Figure 6, the prog-
nostic associations of these three NFκB and AP-1 upregu-
lated genes were further evaluated in node-negative ER-
positive breast cancer cases identified from three other
published data sets (Rotterdam, n = 209; Amsterdam, n =
68; Basel, n = 108), each with different patient age and
adjuvant tamoxifen treatment characteristics and none
fully consistent with the UCSF characteristics (21, 27, 28).
Across all three datasets, higher levels of the NFκB and AP-
1 upregulated genes were generally associated with worse
outcome although the outcome differences between the
high/low dichotomized cases often did not reach statisti-
cal significance (p < 0.05). In the older age, tamoxifen-
untreated Rotterdam cases and in the younger age,
tamoxifen-untreated Amsterdam cases only VEGF showed
significant prognostic impact; in the older age, tamoxifen-
treated Basel cases only uPA showed significant prognostic
Comparison of drug treatment effects on expression of (ERE)-luciferase (A), (NFκB)-luciferase (B), and (AP-1)-luciferase (C)  reporter genes in TAM-resistant (MCF7/HER2, BT474) and TAM-sensitive (MCF7) breast cancer cells Figure 3
Comparison of drug treatment effects on expression of (ERE)-luciferase (A), (NFκB)-luciferase (B), and (AP-1)-luciferase (C) 
reporter genes in TAM-resistant (MCF7/HER2, BT474) and TAM-sensitive (MCF7) breast cancer cells. As described in Meth-
ods, cell cultures were transiently transfected with the specific reporter plasmid 20 h before a 24 h culture treatment with the 
indicated dose of either PS341 or PA, alone or in combination with TAM (500 nM). Reporter activity (firefly luciferase) is pre-
sented as mean ± SE fold induction over vehicle treated control cells. * p < 0.05, for drug alone vs. vehicle control; # p < 0.05, 
for TAM-PS341 or TAM-PA combinations vs. PS341 or PA alone.
A.
B.
C.BMC Cancer 2007, 7:59 http://www.biomedcentral.com/1471-2407/7/59
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impact. Consistent with the UCSF results, when all three
NFκB and AP-1 upregulated genes were combined to pro-
duce four subsets within each dataset, the resulting Kap-
lan-Meier curves showed a rank order correlation between
increasingly worse outcome and number of high express-
ing genes (HHH > HHL > HLL > LLL); although these out-
come differences did not quite reach statistical
significance by Log Rank analysis, in each dataset those
cases showing high expression of all three NFκB and AP-1
upregulated genes (HHH) exhibited median times to met-
astatic recurrence ≤ 5 years (data not shown).
Discussion
A number of gene signature studies have now demon-
strated that ER-positive breast cancers can be subset into
those associated with good patient prognosis and those at
higher risk for metastatic relapse despite adjuvant endo-
crine therapy [32,34-36]. Other preclinical and clinical
evidence links TAM-resistant ER-positive breast cancer
with co-expression of one or more members of the ERBB/
HER family of membrane receptor tyrosine kinesis
[32,33,37-40], activation of insulin-like growth factor
receptors [41], and/or constitutively active downstream
signal transduction pathways (e.g. Ras/Raf, PKC, MAPK,
PI3K/AKT/mTOR) capable of crosstalking with ER [38,42-
45]. These ER interfering signals all converge on two tran-
scription factor complexes, AP-1 and NFκB, also found
activated in high-risk subsets of ER-positive breast cancer
relapsing early on TAM therapy [17,19]. A recent analysis
of 59 early stage ER-positive breast cancers, diagnosed
across all age groups and treated with adjuvant TAM, iden-
tified increases in both NFκB (p50) and AP-1 DNA-bind-
ing as co-predictors of early metastatic relapse [19]. Cross
correlation of these two parameters with numerous other
protein biomarkers formerly evaluated in the same tumor
set also identified a strong association with uPA expres-
Comparison of drug treatment effects on ER and ER binding to the transcriptional co-repressor, NCoR, in TAM-resistant  (MCF7/HER2, BT474) and TAM-sensitive (MCF7) breast cancer cells Figure 4
Comparison of drug treatment effects on ER and ER binding to the transcriptional co-repressor, NCoR, in TAM-resistant 
(MCF7/HER2, BT474) and TAM-sensitive (MCF7) breast cancer cells. Cell cultures were treated for 24 h with vehicle, PS341 
(panel A), or PA (panel B), alone or in combination with TAM (500 nM). Whole cells were then extracted and Western blot-
ted to detect total ER relative to β-actin, or immunoprecipitated (IP) and then Western blotted (WB) to detect NCoR-bound 
ER relative to total immunoprecipitated NCoR.
TAM (500nM)           -      +     -      +     -      +            -       +     -    +     -      +             -     +      -     +    -      +
    PS341 (nM)          0     0    10   10   25    25           0      0   10   10   25   25            0     0    10   10   25   25
ERα
β-actin
MCF7 MCF7/HER2 BT474
IP: NCoR
WB: ERα
TAM (500nM)          -      +      -     +     -     +               -      +     -    +      -     +               -     +     -    +     -      +
         PA (μM)         0     0      1     1    5     5               0     0     1    1     5     5               0    0     1    1     5     5
ERα
β-actin
IP: NCoR
WB: ERα
A.
B.
IP: NCoR
WB: NCoR
IP: NCoR
WB: NCoRBMC Cancer 2007, 7:59 http://www.biomedcentral.com/1471-2407/7/59
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sion [19], an established prognostic marker for node-neg-
ative breast cancer [28] transcriptionally controlled by the
cooperative transactivation of both NFκB and AP-1 [23].
Thus, this study introduced the possibility that ER-posi-
tive breast cancers at risk for antiestrogen resistance and
early metastatic relapse might be identified at diagnosis by
elevated expression of genes transcriptionally upregulated
by NFκB and AP-1. Still to be defined, however, was the
mechanistic rationale for a therapeutic intervention that
could prevent the activation of NFκB and AP-1 and
thereby restore antiestrogen sensitivity to such high-risk
ER-positive breast cancers.
In the present study, two TAM-resistant ER-positive/
ERBB2-positive breast cancer cell lines (MCF7/HER2 and
BT474) and one TAM-sensitive ER-positive/ERBB2-nega-
tive breast cancer cell line (MCF7) were used to model the
effects of TAM treatment on breast cancers with either low
or high levels of NFκB and AP-1 transcriptional activity,
and assess the TAM interacting effects of drugs (PA,
PS341) potentially capable of lowering NFκB and AP-1
activities. These cell lines are considered relevant experi-
mental models since TAM acts as a growth antagonist in
MCF7 but shows little growth inhibiting activity against
BT474 and can actually stimulate growth of MCF7/HER2
Kaplan-Meier relapse-free survival of 54 UCSF node-negative, ER-positive breast cancer cases by age cohort (≥ 70, ≤ 45 years)  and with outcomes dichotomized for tumor expression (high, low) of the NFκB and AP-1 regulated genes cyclin D1, uPA, and  VEGF Figure 5
Kaplan-Meier relapse-free survival of 54 UCSF node-negative, ER-positive breast cancer cases by age cohort (≥ 70, ≤ 45 years) 
and with outcomes dichotomized for tumor expression (high, low) of the NFκB and AP-1 regulated genes cyclin D1, uPA, and 
VEGF. As described in Methods, the 54 node-negative cases were balanced between cohorts for standard prognostic markers 
and adjuvant TAM treatment (>60%). Gene transcript levels were quantified using a commercial microarray platform with 
standard data processing (Affymetrix); cases were designated high or low expressors based on mean-centered gene expres-
sion. Significant differences between the cumulative survival curves were determined by Log Rank analyses (only p values < 0.05 
shown)BMC Cancer 2007, 7:59 http://www.biomedcentral.com/1471-2407/7/59
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[18], similar to clinical observations with TAM treated ER-
positive/ErbB2-positive breast cancers [33]. While the
TAM-resistance displayed by MCF7/HER2 and BT474
undoubtedly results from their constitutively activated
ERBB2 signaling, the present studies demonstrated that
these models exhibit significantly increased NFκB (Figure
1) and AP-1 (Figure 2) DNA-binding and gene upregulat-
ing activities. Unlike observations with MCF7 cells, TAM
treatment failed to significantly suppress (ERE)-luc
reporter gene activity in MCF7/HER2 and BT474 cells
(Figure 3A), and produced only attenuated recruitment of
the co-repressor NCoR to TAM-bound ER (Figure 4). Ear-
lier studies comparing parental MCF7 with MCF7/HER2
had demonstrated that both cell lines express comparable
levels of NCoR, and that TAM treatment of MCF7/HER2
fails to result in NCoR recruitment by ER but inhibition of
ERBB2 signaling can restore ER-NCoR binding in MCF7/
HER2 compareble to that seen in MCF7 cells [46].
Kaplan-Meier metastasis-free survival of node-negative ER-positive breast cancer cases identified from three independent data  sets (Rotterdam, Amsterdam, Basel), with outcomes dichotomized for tumor expression (high, low) of the NFκB and AP-1  regulated genes cyclin D1, uPA, and VEGF Figure 6
Kaplan-Meier metastasis-free survival of node-negative ER-positive breast cancer cases identified from three independent data 
sets (Rotterdam, Amsterdam, Basel), with outcomes dichotomized for tumor expression (high, low) of the NFκB and AP-1 
regulated genes cyclin D1, uPA, and VEGF. As described in Methods, the Rotterdam cases (n = 209) represented patients of all 
ages (26–83 years), none of whom received any adjuvant therapy; gene transcripts were measured by commercial (Affymetrix) 
microarray platform, and high/low dichotomization based on mean centered expression levels. The Amsterdam cases (n = 68) 
represented young patients (all < 55 years), only 5% of whom received adjuvant TAM; gene transcripts were measured by 
commercial (Agilent) microarray platform, and high/low dichotomization based on positive/negative log10 gene expression 
ratios. The Basel cases (n = 108) represented patients of all ages (37–84 years), 70% of whom received adjuvant TAM therapy; 
gene transcripts were measured by quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) assay, 
and high/low dichotomization based on median cut-point gene transcript levels. Significant differences between the cumulative 
survival curves were determined by Log Rank analyses (only p values < 0.05 shown).BMC Cancer 2007, 7:59 http://www.biomedcentral.com/1471-2407/7/59
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Rather than inhibit upstream ERBB2 signaling, the
present approach was designed to inhibit downstream
NFκB and AP-1 activation in the TAM-resistant breast can-
cer models. PA and PS341, at doses capable of enhancing
TAM induced growth inhibition of MCF7/HER2 and
BT474 cells (Table 1), reduced NFκB and AP-1 driven gene
expression (Figures 3B, C); and, in combination with a
TAM dose that alone had no effect on these reporter genes,
TAM-PA and TAM-PS341 combinations more substan-
tially reduced NFκB and AP-1 driven gene expression but
only in the TAM-resistant cells having constitutively ele-
vated NFκB and AP-1 activity. These same TAM-PA and
TAM-PS341 combinations were able to restore the levels
of NCoR binding to TAM-liganded ER in the MCF7/HER2
and BT474 cells toward that observed in the TAM-sensi-
tive MCF7 cells. A more general extrapolation of these
results would suggest that direct inhibition of constitu-
tively elevated NFκB and AP-1 transcriptional activities,
caused by any number of oncogenic stimuli and signaling
pathways, can improve the endocrine responsiveness of
otherwise TAM-resistant ER-positive breast cancers by
enhancing NCoR recruitment to TAM-liganded ER,
thereby suppressing expression of growth and metastasis
promoting genes upregulated by both NFκB and AP-1.
Looking for preliminary evidence of growth and metasta-
sis promoting genes coordinately upregulated by both
NFκB and AP-1, expression microarray data available
from 54 UCSF node-negative ER-positive breast cancers
with known clinical outcome revealed three such genes
capable of dichotomizing these cases into early and late
relapsing subsets despite adjuvant tamoxifen therapy: cyc-
lin D1, uPA and VEGF (Figure 5). Not only are these gene
candidates known to be transcriptionally upregulated by
the coordinated activation of both NFκB and AP-1 [22-
26], their overexpression has been linked to clinically
aggressive forms of breast cancer and, in some cases, to
tamoxifen resistance [28,47,48]. For unrelated study pur-
poses [20], these ER-positive tumor samples had been
preselected from two different age-at-onset breast cancer
case populations (young, ≤ age 45; older, ≥ 70), but were
otherwise indistinguishable with regard to standard prog-
nostic markers and systemic adjuvant therapy including
TAM. While overexpression of these three NFκB and AP-1
upregulated genes at the protein level has been well docu-
mented for clinically aggressive breast cancers, their prog-
nostic impact at the transcript level had not been
previously recognized for ER-positive breast cancer. Of
interest, the prognostic value of these genes measured by
separation in Kaplan-Meier RFS curves appeared greater
for the younger age-at-onset cases, in which there were
overall more metastatic relapses than for the older age-at-
onset cases, despite the fact that both age groups showed
similar median and range transcript values for each of the
gene candidates. Since higher expression of more than
one of these three genes might be expected given a com-
mon NFκB and AP-1 upregulating transcriptional mecha-
nism, it is of interest that the 26 cases showing 2/3 (HHL)
or 3/3 (HHH) of these upregulated genes showed signifi-
cantly worse RFS outcomes than the 28 cases with fewer
upregulated genes (HLL, LLL), and that the 10 early stage
ER-positive breast cancers with all three upregulated genes
had the poorest outcome with a median RFS of < 5 years.
The associations of cyclin D1, uPA and VEGF with patient
outcome were tested in node-negative ER-positive breast
cancer cases identified from three other independent data-
sets (21, 27, 28), each with different patient age and adju-
vant tamoxifen treatment characteristics and none
comparable to the younger age, tamoxifen-treated UCSF
cases in which these three genes exhibited their greatest
prognostic impact. Identified from these other datasets
were 209 older age, tamoxifen-untreated Rotterdam cases,
68 younger age, tamoxifen-untreated Amsterdam cases,
and 108 older age, tamoxifen-treated Basel cases. Consist-
ent with the UCSF results, higher expression levels of
these three NFκB and AP-1 upregulated genes in the other
datasets were generally associated with worse outcomes,
individually and collectively, although many of these dif-
ferences did not quite reach statistical significance. It is
important to note that no effort was made to optimize the
high/low median value cut-points arbitrarily chosen for
the UCSF outcome analysis and subsequently applied to
the other datasets. Generalizing from all four datasets it
might be suggested that as individual prognostic factors,
VEGF appeared least dependent on age-at-diagnosis and
adjuvant tamoxifen status, uPA appeared most useful in
tamoxifen treated cases, and the impact of cyclin D1
appeared limited to younger cases. Evaluating the three
NFκB and AP-1 upregulated genes collectively across all
four datasets and weighting them equally demonstrated
that node-negative ER-positive cases with high level
expression of all three genes (HHH) experience the earli-
est metastatic relapses (median recurrence intervals ≤ 5
years).
While exploratory and preliminary in nature, these tran-
script expression results indicate that genes coordinately
upregulated by NFκB and AP-1 may be implicated in the
clinical behavior of ER-positive breast cancers resistant to
tamoxifen and destined for early relapse. Since the tran-
scriptional activities of NFκB and AP-1 complexes are not
directly measurable in clinical breast cancer samples,
prognostic signatures reflecting these activities would help
to identify high-risk ER-positive breast cancers in need of
more aggressive adjuvant therapy. Although cyclin D1,
uPA and VEGF are known to be transcriptionally upregu-
lated by NFκB and AP-1, the promoters of these three
genes are also regulated by numerous other transcription
factors which no doubt possess variable activities in oth-BMC Cancer 2007, 7:59 http://www.biomedcentral.com/1471-2407/7/59
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erwise similar ER-positive node-negative breast cancers,
likely contributing to the variable prognostic impact of
these genes observed across the four independent data-
sets. Based on the outcome associations demonstrated
here for uPA,  cyclin D1, and VEGF  transcript levels as
extracted from frozen breast cancer samples and quanti-
tated by different assay platforms, future studies might
consider validating this minimal gene signature set using
RNA extracted from formalin-fixed and paraffin-embed-
ded breast cancer samples, much like the recently
approved OncoType DX® (Genomic Health) assay which
employs a 21-gene signature set to identify ER-positive
node-negative breast cancers in need of aggressive adju-
vant therapy [49]. As well, a validated gene signature set
representing constitutively activated NFκB and AP-1 activ-
ity in ER-positive breast cancers might be used to identify
patients who would be optimally treated with an anties-
trogen in combination with an NFκB and AP-1 down-reg-
ulating drug [11,50]. Such drugs might include a
proteasome inhibitor (e.g. bortezomib, NPI-0052), an
IKK inhibitor (e.g. BAY11-7085, BMS-345541, MLN-
0415), or even phytochemicals like curcumin, resveratrol
or epigallocatechin gallate. Based on the TAM-PA and
TAM-PS341 combinations evaluated here, a TAM-sensitiz-
ing drug dose affecting a high-risk ER-positive breast can-
cer would be expected to restore ER-NCoR binding and
could be monitored during therapy by tumor reduction in
the validated NFκB and AP-1 gene expression signature.
Conclusion
The findings presented here implicate increased NFκB and
AP-1 transcriptional responses in tamoxifen resistant ER-
positive breast cancer models. A minimal set of transcripts
reflecting NFκB and AP-1 upregulated genes may be able
to identify node-negative ER-positive primary breast can-
cers at risk for early clinical relapse despite tamoxifen ther-
apy. Agents capable of preventing NFκB and AP-1 gene
activation may be able to improve the antiestrogen
responsiveness of such high-risk ER-positive breast can-
cers.
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